Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital slightly lowers target price on Grafton

(Sharecast News) - Analysts at RBC Capital Markets slightly lowered their target price on builders merchants Grafton from 1,220p to 1,190p on Friday, as it pushed out the group's recovery. RBC Capital said it likes Grafton for its proven quality, earnings recovery potential and balance sheet firepower, but stated that it move to push out the group's recovery had drived a -1.5%/-10.8%/-11.1% reduction to its FY25-27 adjusted earnings per share estimates and left it in line with consensus for FY25 and 4% below in FY26/27.

The Canadian bank sees recovered adjusted earnings per share at more than 98p, excluding 10-20% accretion potential from its roughly £300m firepower, rising to approximately £475m.

"Assuming a 50-50 split between buybacks and M&A, £475m could drive c.20% adj. EPS accretion by FY27e. On a more conservative approach, maintaining the capital allocation run rate of c.£120m p.a. (average since FY19) implies c.10% accretion to FY27e, incremental to our estimates. Boltons in Iberia appear the most likely candidate, in our view," said RBC, which reiterated its 'outperform' rating on the stock.

RBC added that Grafton trades on 13.1x CY26e price-to-earnings ratio, falling to roughly 10x on recovered adjusted earnings per share, versus its 14x long-term average.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.